CUE vs EPAM · rev $9.3M vs P/E 14, rev $4.73B
Cue Biopharma (CUE) versus EPAM Systems Inc (EPAM) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
EPAM Systems Inc (EPAM) is a information technology services company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported EPAM revenue for 2024-12-31 was $4.73B. Net income was $454.5M. Revenue was up 0.8% from 2023-12-31 to 2024-12-31. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
CUE currently screens at market cap $59.5M. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
Not investment advice. Open the CUE and EPAM stock pages for the full models.
Not investment advice.